Skip to main content

Table 1 Demographic and basic clinical parameters at treatment start

From: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

Baseline parameter Females Males Overall
N (%) 24 (53.3) 21 (46.7) 45
Age, mean (SD), years 38.6 (14.2) 30.2 (9.5) 34.7 (12.8)
Age at ERT start, mean (SD), years 38.7 (14.1) 30.2 (9.5) 34.7 (12.8)
Age at ERT start, median (range), years 37.2 (15.6–61.4) 31.4 (14.9–44.9) 34.5 (14.9–61.4)
BMI, mean (SD), kg/m2 23.5 (3.6) 21.6 (3.5) 22.6 (3.6)
Systolic BP, mean (SD), mmHg 127.3 (13.2) 126.2 (16.0) 126.8 (14.4)
Diastolic BP, mean (SD), mmHg 72.3 (9.1) 68.2 (10.3) 70.4 (9.8)
Heart rate, mean (SD), bpm 64.0 (13.1) 65.1 (7.7) 64.5 (10.8)
Diabetes, n (%) 0 (0) 0 (0) 0 (0)
Current smoker, n (%) 2 (8.3) 3 (14.3) 5 (11.1)
Arterial hypertension, n (%) 2 (8.3) 3 (14.3) 5 (11.1)
  1. BMI: body mass index; bpm: beats per minute; BP: blood pressure; ERT: enzyme replacement therapy; SD: standard deviation